uniQure (NASDAQ: QURE) updates on AMT-130; FDA feedback shifts, BLA timing unclear

stocktitan.net/news/QURE/uni-qure-provides-regulatory-update-on-amt-130-for-huntington-s-go0k2ksf4qls.html

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
uniQure (NASDAQ: QURE) on Nov. 3, 2025 announced FDA feedback from a pre-BLA meeting for AMT-130, its investigational gene therapy for Huntington’s disease.
uniQure said the FDA now appears to disagree that Phase I/II…

This story appeared on stocktitan.net, 2025-11-03 12:59:34.656000.
The Entire Business World on a Single Page. Free to Use →